LumiraBPC-157
Ordered BPC-157 from Lumira? Mail in a sample (US only) and let us test it for free.
Test my supplyLumira's purity-focus record is strongest in GHK-Cu and improving in Tirzepatide, where recent identity and purity results generally clear the bar. Retatrutide and Tesamorelin are volatile, with recent identity/purity failures offset by rebounds; evidence is current but batch documentation is uneven.
Domain and contact records tie Lumira to the Welon/Peptidecube stack while US-shipping language points another way. The report maps privacy-protected domains, referral-code promotion, and payment/refund friction.
Unlock original COAs
View and download original lab PDFs for Finnrick tests, including Lumira rows.
Cancel anytime
About Lumira test results from Finnrick
Lumira is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 9 peptides and 68 tests, including ratings, observed price signals, recent test dates, and correction history where available.
Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.
The most visible Lumira peptides in this dataset are BPC-157 (4 tests), GHK-Cu (11 tests) and GLOW (1 test). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.
Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 68 recent tests. It also includes 2 corrections related to this vendor.
Ordered BPC-157 from Lumira? Mail in a sample (US only) and let us test it for free.
Test my supply